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Case presentation
An 85-yr-old woman was transferred to New England Medical
Center Hospital (NEMCH) for management of acute renal failure
(ARF). The patient was in apparent good health until 3.5 weeks
earlier when she had a uterine prolapse and was admitted to an-
other hospital. Her blood urea nitrogen (BUN) concentration,
serum creatinine concentration, and results of urinalyses were
normal. An electrocardiogram (EKG) revealed an old infer-
olateral myocardial infarction. The patient underwent a vaginal
hysterectomy; in the immediate postoperative period she com-
plained of chest pain. Over the week following the operation,
EKG changes revealed the evolution of a new anterior myo-
cardial infarction. During this same interval, several blood trans-
fusions were required because of persistent vaginal bleeding.
During one of these transfusions approximately 10 days prior to
transfer to NEMCH, the patient developed a fever (41° C), shak-
ing chills, and hemoglobinuria. She was treated with Benadryl
and Solu-medrol. EKG revealed new Q waves in the inferior
leads. Clindamycin, gentamicin, and nafcillin were also adminis-
tered at this time. Over the next 10 days, urine output decreased,
and the serum creatinine concentration increased. A Giovanetti
diet and fluid restriction were instituted; the antibiotics were
continued but in reduced dosage. Urine output remained in the
range of 200 to 300 mI/day. At the time of transfer to NEMCH,
the serum creatinine concentration was 12 mg and the BUN con-
centration was 130 mg/lOO ml.
On admission to NEMCH, physical examination revealed the
following: blood pressure, 170/80 mm Hg; temperature, 38.5° C;
pulse, 68/mm; respirations, 20/mm; the skin had an erythematous
maculopapular rash over the trunk; head, ears, eyes, nose, and
throat were within normal limits; no jugular venous distention;
the lungs had bibasilar dry rales and decreased breath sounds
bilaterally with diffuse expiratory wheezes. Cardiac examination
revealed a diffuse point of maximal impulse in the midclavicular
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line with no heave; normal Sl and S2; a grade IVVI systolic ejec-
tion murmur along the lower left sternal border; and no thrills
rubs, or gallops. Abdominal and neurologic examinations were
unremarkable. Pelvic examination revealed no masses or tender-
ness. There was no peripheral edema. Laboratory findings dis-
closed the following data: hemoglobin, 10.5 g/l00 ml; hematocrit,
30%; white blood cell (WBC) count, 7,200 mm3 with a normal dif-
ferential; serum sodium, 129 mEq; serum potassium, 5.6 mEq;
serum chloride, 95 mEq; total carbon dioxide, 14 mEq/liter;
BUN, 132 mg; serum creatinine, 12.9 mg; serum calcium, 7.8
mg; serum glucose, 82 mg/100 ml; arterial oxygen tension, 81 mm
Hg; arterial carbon dioxide tension, 28 mm Hg; arterial pH,
7.29. EKG revealed a normal sinus rhythm at the rate of 70/mm:
a prominent Q wave in lead 3; and biphasic Q waves in AVL, V3,
and V4. Results of urinalyses revealed the following: pH, 5;
many red blood cells (RBC); a few WBC; and a few tubular epi-
thelial cells. A radiograph of the chest revealed the trachea to
be deviated slightly to the right and a few old calcified granu-
lomas. Renal scan and abdominal echogram revealed bilateral
kidneys of normal size and no evidence of obstruction.
For the first 36 hours of hospitalization, the patient underwent
peritoneal dialysis (approximately 30 exchanges) during which
the BUN concentration decreased to 59 mg and the serum creati-
nine concentration to 9.4 mgIlOO ml. Following dialysis, the pa-
tient's serum creatinine concentration increased slightly to 10.1
mg/l00 ml; it then decreased over the next 2 weeks to 1.9 mg/lOO
ml. The patient was discharged 17 days following admission.
Discussion
DR. R. W. SCHRIER: This 85-yr-old patient under-
went a vaginal hysterectomy complicated by an an-
terior myocardial infarction and some postoperative
bleeding, which required blood transfusions. One of
these transfusions was accompanied by fever,
chills, hemoglobinuria, and possibly another myo-
cardial infarction. In addition to treatment of the
presumed transfusion reaction with Benadryl and
Solu-medrol, several antibiotics (clindamycin, gen-
tamicin, and nafcillin) were started. Immediately af-
ter this transfusion episode, the patient's serum
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creatinine concentration began to rise progressive-
ly, as her urine output remained in an oliguric range
(<400 m1124 hr). Ten days after the transfusion re-
action, the patient was transferred to NEMCH with
a serum creatinine concentration of 12 mgIlOO ml
and a BUN concentration of 130 mgIlOO ml. The
positive findings of the physical examination were a
maculopapular rash of the trunk, bibasilar dry rales,
and a systolic murmur. The laboratory findings
were compatible with uremic metabolic acidosis
and also revealed hypocalcemia, hyponatremia, and
hyperkalemia. Results of urinalysis demonstrated
hematuria and pyuria.
Predisposing factors. This patient was pre-
disposed to develop ARF for several reasons: (1)
advanced age, (2) persistent bleeding with probable
hypovolemia, (3) recent myocardial infarction, and
(4) recent anesthesia.
It is known that ARF occurs more frequently in
older individuals, and that the mortality rate associ-
ated with ARF is higher than in other age groups
[1]. Renal function is known to deteriorate with age,
so that an 85-yr-old person is normally expected to
have a creatinine clearance of only some 45 mL'min
12]. It also is possible that advancing age impairs the
protective mechanisms of renal autoregulation and
renal prostaglandin release, which are evoked dur-
ing vasoconstrictive insults, but this speculation re-
mains to be studied. Moreover, it is important to
recall that the presence of inhibitors of prostaglan-
din synthesis (e.g., aspirin, indomethacin, phenyl-
butazone, ibuprofen, and naproxen), which are
widely used for treatment of arthritis in the aged,
may predispose the kidney to more severe ischemia
whenever a hemodynamic insult occurs 113, 4].
The patient described here had continued bleed-
ing prior to the episode of hemoglobinemia and he-
moglobinuria. Experimental evidence in AFR mod-
els indicates that fluid deprivation and volume de-
pletion potentiate the development of pigment-
induced (hemoglobin, myoglobin) ARF [5].
The postoperative complication of myocardial in-
farction must be considered in this patient's course
toward ARF. A myocardial infarction can result in
renal ischemia if the degree of myocardial dysfunc-
tion and decrease in cardiac output is sufficiently
great. If cardiac failure occurs, however, the con-
comitant increase in left atrial pressure may exert
an early protective effect on renal function. An in-
crease in left atrial pressure initiates a reflex that
decreases renal sympathetic tone and tends to vaso-
dilate the kidney [6]. This phenomenon may ac-
count for the clinical aphorism that patients with an
acute myocardial infarction do not develop ARF.
This is of course not an absolute dictum; it is true,
however, that for a given decrement in blood pres-
sure, the degree of renal ischemia is less during car-
diac failure (increase in left atrial pressure) than it is
during hemorrhage (decrease in left atrial pressure)
[7]. Finally, the occurrence of hematuria and renal
functional deterioration in association with a recent
myocardial infarction should always alert the clini-
cian to the possibility of a mural thrombus with em-
boli to the kidney, Cardiac ultrasound and a renal
scan are valuable tools for the detection of this dis-
order.
Whenever renal failure follows a recent operative
procedure, it is important to discern whether the
anesthetic used might be contributing to renal diffi-
culty. Halothane and methoxyflurane are the anes-
thetics most frequently mentioned as potential etio-
logic factors in causing renal deterioration [8, 9].
The renal toxicity of halothane is generally associat-
ed with hepatic damage and with the consequent re-
lease of tissue thromboplastin, which is then fol-
Idwed by intravascular coagulation and renal corti-
cal necrosis. The renal toxicity of methoxyflurane
appears to relate more closely to the resulting in-
crease in plasma fluoride concentration than to the
increase in oxalate excretion 119]. If microsomal en-
zymes in the liver have been induced by previous
use of the anesthetic or by phenobarbital adminis-
tration, then repeat exposure to methoxyflurane
may result in more rapid metabolism of the drug and
a higher concentration of plasma fluoride. Enflu-
rane, a fluoride-containing anesthetic, releases less
fluoride on metabolism than methoxyflurane; this
probably explains the agent's lower renal toxicity
[10]. It is interesting, however, that renal toxicity
with enflurane has been described in the setting of
prior use of the anesthetic and a high plasma fluo-
ride concentration [111. In the patient we are dis-
cussing here, although we are not told the nature of
the anesthetic used, the length of time between the
operation and the onset of renal failure would dis-
miss the anesthetic as a primary cause of renal fail-
ure. If reoperation for continued vaginal bleeding
had become necessary, however, it would be im-
portant to know if a fluoride-containing anesthetic
had been used in the earlier operation. An elevated
serum fluoride concentration may persist for a week
after methoxyflurane administration 11101; whether
such elevation predisposes the kidney to toxicity
with other nephrotoxic agents remains to be stud-
ied.
Etiologic factors. As is often the case, this patient
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not only had several factors predisposing her to de-
velop ARF, she also encountered multiple agents
and conditions of potential importance in the etiol-
ogy of ARF; these include (1) nephrotoxic amino-
glycosides, (2) penicillin homologues capable of
triggering acute interstitial nephritis, (3) recurrent
acute myocardial infarction, (4) septicemia, and (5)
transfusion reaction with hemoglobinuria.
The aminoglycosides have become the most re-
lied on antibiotics in the treatment of gram-negative
bacterial infections. The aminoglycoside introduced
first, neomycin, has been restricted to oral or topi-
cal use because of its nephrotoxic potential. The
aminoglycosides now used are less nephrotoxic but
all of them, including kanamycin, gentamicin,
amikacin, sisomicin, and tobramycin, can cause im-
pairment in renal function. One of the newest
aminoglycosides, netilmicin, may offer the hope of
a comparable antimicrobial spectrum with less
nephrotoxicity [12]. The nephrotoxicity of the
aminoglycosides probably relates to tissue-binding
of the drug in the renal cortex [13], and the degree
of tissue-binding appears to correlate with the num-
ber of free amino groups contained in a given agent
[14]. Strikingly, the most nephrotoxic amino-
glycoside, neomycin, has six free amino groups,
and the least nephrotoxic, streptomycin, has only
two free amino groups. Aminoglycosides remain
bound to renal tissue long after the antibiotic has
disappeared from the circulation; the half-life of
aminoglycosides in serum is 30 mm, but in renal tis-
sue it is 109 hours [15]. Four weeks after a single
injection of gentamicin in the rat, a therapeutic tis-
sue concentration of 6 g/g of tissue may persist
[16]. This long tissue half-life no doubt explains why
the onset of renal failure secondary to amino-
glycosides has been reported to occur as late as sev-
eral days after administration of the antibiotics has
been discontinued. Cytosomes containing altered
cell organelles (lysosomal cytosegrosomes) and
lysosomal ingestion of phospholipid membranes
(myeloid bodies) are characteristically found in the
proximal tubular epithelium of patients treated with
aminoglycosides; these anatomical changes, how-
ever, do not necessarily correlate with the degree of
renal functional impairment [17].
Several factors are known to predispose patients
to the development of aminoglycoside nephrotoxic-
ity: (1) advancing age, (2) preexistant renal dysfunc-
tion, (3) volume depletion, (4) recent exposure to
aminoglycoside or another nephrotoxic agent. The
older the patient is, the greater the likelihood that
aminoglycoside toxicity will occur [18]. This effect
may be partially explained by the failure of clini-
cians to decrease the drug dosage in proportion to
the decrease in glomerular filtration rate (GFR) that
occurs with age. Preexisting renal dysfunction is an-
other factor that predisposes patients to amino-
glycoside nephrotoxicity [18]. Sodium restriction
and volume depletion increase the incidence of
aminoglycoside nephrotoxicity presumably because
they serve to increase the cortical concentrations of
the drug [19]. In one study, the incidence of amino-
glycoside nephrotoxicity increased from 7 to 22% in
patients who had recent exposure either to amino-
glycosides or to other potentially nephrotoxic
agents [18]. The patient described here was elderly,
probably was somewhat volume depleted because
of continued bleeding, may have been recently ex-
posed to a nephrotoxic anesthetic, and was treated
with the combination of gentamicin and clindamy-
cm. It has been suggested that the latter agent may
increase the nephrotoxic effect of aminoglycosides
[20]. Furosemide administration frequently poten-
tiates aminoglycoside nephrotoxicity probably be-
cause of the diuretic's potent volume-depleting ef-
fect [21]. The ability of cephalosporins to increase
aminoglycoside renal toxicity is not as well estab-
lished; in fact, the results of one experimental study
even suggest that cephalosporins decrease renal
cortical tissue concentrations of aminoglycosides
and thus protect against nephrotoxicity [22].
The clinical course of aminoglycoside nephrotox-
icity is, however, quite different from that observed
in this patient. The nephrotoxic effect of amino-
glycosides is generally gradual in onset and related
to the dose and duration of drug administration [23].
A nonoliguric, self-limited form of ARF with a low
mortality is most common with aminoglycoside
nephrotoxicity [24]. It would be extremely rare for
one to two doses of the drug to cause acute onset of
oliguria and azotemia, as was observed in the pa-
tient presented here. In general, proteinuria, lyso-
zymuria, and a renal concentrating defect with
polyuria precede any decrease in GFR with amino-
glycoside toxicity [13]; azotemia and glucosuria are
later consequences of toxicity [25]. Since amino-
glycosides are eliminated primarily by glomerular
filtration, whenever serum creatinine concentration
increases, the "trough" concentration of the antibi-
otic will also increase unless the dose has been al-
tered. Thus, the serum creatinine concentration can
be used to gauge the "trough" concentration of se-
rum aminoglycoside when the latter measurement is
unavailable.
Acute interstitial nephritis has become a more
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frequently recognized cause of ARF. The drugs as-
sociated with this renal hypersensitivity reaction
include sulfonamides, sulfonamide diuretics, furo-
semide, diphenylhydantoin, cephalosporins, phen-
ylbutazone, allopurinol, phenindione, rifampin, pen-
icillin and penicillin-homologues [26-32]. These
reactions are generally associated with increased
eosinophils in blood and urine: A Wright's stain of
the urine is useful in detecting the eosinophiluria.
Fever and skin rash are also frequent findings. This
elderly woman received nafcillin and had a skin
rash, thus suggesting the possibility of interstitial
nephritis. The patient's fever, however, preceded
the occurrence of the ARF. The immediate onset of
the oliguria on the first day of penicillin homologue
administration would be rare unless an amnestic re-
action had occurred. No previous history of pen-
icillin allergy, however, was noted. The patient's
pyuria and hematuria are compatible with the diag-
nosis of acute interstitial nephritis.
The possible occurrence of another myocardial
infarction, as evidenced by the finding of new Q
waves, and septicemia also may have contributed to
the ARF. Although fever and shaking chills oc-
curred during the administration of a blood trans-
fusion, other causes of fever must be considered.
Culture of both the patient's blood and the trans-
fused blood would have been helpful. ARF associ-
ated with septicemia is more common in the older
age group. Immune complex glomerular disease as-
sociated with bacterial endocarditis [33] and abdom-
inal abscesses [34] also might be considered, but
again the rapidity of the onset of ARF in this patient
makes both of these possibilities unlikely. A de-
crease in serum complement concentration, RBC
casts in the urine, and positive blood cultures are
important diagnostic features of diffuse proliferative
glomerulonephritis associated with bacterial endo-
carditis [33]; none of these were noted in this pa-
tient. In patients with abdominal abscesses, how-
ever, neither positive blood cultures nor decreased
serum complement concentrations are consistent
findings [34].
Despite the profusion of potential predisposing
and etiologic factors, the temporal association be-
tween the transfusion reaction with hemoglobinuria
and the onset of oliguria provides the most likely
explanation for the ARF in this patient. It is note-
worthy that hemoglobin infusion alone has not pro-
vided a reproducible model of ARF; it appears that
the addition of RBC stroma, or prior volume deple-
tion, or both may play a critical role [35]. It is also
important to emphasize that the presence of a ben-
zidine positive pigment in the RBC-free supernatant
of the urine does not distinguish between hemo-
globinuria and myoglobinuria. Myoglobinuria has
come to be recognized more frequently as a cause
of ARF [36]; as with hemoglobinuria, however, pre-
disposing factors are important. Since myoglobin
(mol wt, 17,000 daltons) is much smaller than he-
moglobin (mol wt, 69,000 daltons) and since only
hemoglobin has a plasma binding protein (hap-
toglobin), the plasma is generally pink with hemo-
globinemia and its normal straw color with myo-
globinemia. Muscle damage secondary to pressure
or trauma, viral infections (e.g., influenza), acute
hypophosphatemia, hypokalemia, alcoholism, and
heroin abuse are examples of important clinical set-
tings in which myoglobinuria may occur. A sub-
stantial elevation in the activity of the muscle en-
zymes (aldolase, creatinine phosphokinase) is a
hallmark of this condition. Unless a sensitive immu-
nologic test is available, it may be very difficult to
establish the presence of myoglobinuria with cer-
tainty; therefore, the diagnosis is generally inferred
by the presence of a benzidine-positive pigment in
the urine in the face of normal appearing serum, ele-
vated muscle enzyme activity in the plasma, and a
proper clinical setting.
Pathophysiology of ARF. In keeping with the
many predisposing and etiologic factors in ARF, the
pathophysiology of this condition also appears to be
multifactoral. This may be the reason why the
pathophysiology of ARF has escaped clear delinea-
tion despite vigorous investigative efforts by many
researchers over the past two decades. Some ad-
vances in our understanding of ARF, however,
have been made. As implied, it now seems unlikely
that any single pathogenetic sequence will account
for all varieties of ARF. In addition, it is important
to distinguish between initiating and maintenance
factors in considering the pathogenesis of ARF. Un-
til recently, the apparent absence of elevated intra-
tubular pressures in a variety of experimental mod-
els of ARF and the presence of decreased renal
blood flow (RBF) led many investigators to use the
term "vasomotor nephropathy" to highlight the
vascular role in the pathogenesis of ARF [37].
While vascular events are no doubt involved in the
initiation of ARF, the maintenance of ARF prob-
ably cannot be explained solely by ischemic events.
This tentative conclusion is based primarily on the
finding that neither spontaneous nor pharmacologic
restoration of normal RBF in man [38] or experi-
mental animals [39, 40] is capable of reversing the
ARF. It is possible, however, that persistent af-
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ferent arteriolar constriction and efferent arteriolar
dilatation obviates restoration of glomerular filtra-
tion pressure despite such restoration of RBF, and
thus maintains the near absence of GFR.
Two recent findings have breathed new life into
the theory that ARF is dependent on intratubular
obstruction. First, the experimental model of ARF
produced by renal artery-clamping in the rat has
been found to be associated consistently with ele-
vated intratubular pressures [41, 421. Second, and
perhaps most important, when RBF is restored in
experimental models of ARF, elevations in intra-
tubular pressures are uncovered that were not de-
tectable in the presence of continued renal ischemia
[43, 44]. These findings are compatible with the no-
tion that relative tubular obstruction is an important
factor in the maintenance of ARF.
The possibility that a decrease in glomerular per-
meability may contribute to the pathogenesis of
ARF has been raised by the finding on scanning
electron microscopy of smudging" of glomerular
epithelial podocytes in a model of ARF produced by
high-dose norepinephrine [45]. The high doses of
norepinephrine used in these studies however
caused irreversible renal failure. When the dose of
norepinephrine is decreased to produce a reversible
form of ARF, there are no detectable changes in the
ultrastructural appearance of the glomerular epithe-
hum [46, 471. Recent studies by scanning electron
microscopy of kidneys from patients with ARF
have also failed to demonstrate any consistent gb-
merular abnormalities [48]. Although some direct
micropuncture studies have found modest changes
in glomerular permeability in experimental ARF
[44, 49], it seems unlikely that this factor is of pri-
mary importance in the pathogenesis of ARF.
It has become common practice to use the histo-
logic term, acute tubular necrosis (ATN), and the
clinical term, ARF, synonymously. Histologic stud-
ies, however, suggest that actual necrosis of tubular
cells may, in fact, be present in only 10 to 20% of
patients with clincial ARF [501. The assumption
that tubular necrosis was more common may have
prompted the suggestion that excessive back-
leak" of glomerular filtrate across damaged tubular
epithelium contributes importantly to the pathogen-
esis of the ohiguria of ARF. Such "back-leak" has
been documented in a few instances in experimental
models of ARF, but generally only when severe
tubular necrosis is produced [5 1—53]. Such a degree
of tubular necrosis, however, does not occur in clin-
ical ARF in man even when caused by nephrotoxic
agents. Moreover, chronic saline loading [54] and
the administration of mannitol [46] or furosemide
[55] respectively can prevent the experimental ARF
ordinarily induced by either mercuric chloride or
norepinephrine, but do not prevent the associated
tubular necrosis.
In summary, an interaction between vascular and
tubular factors seems likely to be involved in the
pathogenesis of ARF. An initial vascular insult may
lead to events that cause relative tubular obstruc-
tion, perhaps secondary to impacted cytoplasmic
blebs [56], and thereby maintain ARF. Changes in
glomerular permeability and excessive "back-leak"
across damaged tubular epithehium also may be
contributing mechanisms, particularly when accom-
panied by severe ischemic insults. In this regard,
the degree of involvement of any of these potential
pathogenetic factors of ARF varies depending on
the nature, severity, and duration of the initial in-
sult.
Clinical diagnosis of ARF. The clinical approach
to the diagnosis of ARF must focus primarily on the
exclusion of immediately reversible prerenal or
postrenal factors [57]. Thus, ARF is a diagnosis of
exclusion. Volume depletion, cardiac failure, and
peripheral vasodilatation are the principal factors
that may cause renal hypoperfusion and thus pre-
renal azotemia. Prolonged prerenal azotemia is
probably the most common cause of ARF. Next,
postrenal or obstructive factors must be excluded
as a cause of azotemia. A postvoid urethral cathe-
terization to assess residual bladder urine volume is
used to exclude bladder neck or urethral obstruc-
tion. A flat plate radiograph of the abdomen can de-
tect the 90% of renal calculi that are radiopaque. As
used in the patient described here, renal ultrasonog-
raphy and renal scan are noninvasive procedures,
which are useful in assessing the presence of upper
urinary tract obstruction. Since the infusion of ra-
diopaque contrast media has been reported with in-
creasing frequency to cause or worsen ARF, high-
dose i.v. pyebography must be used with caution to
exclude urinary tract obstruction [58]. Patients with
diabetes [59], and those with hyperuricemia or mul-
tiple myeboma [60] are particularly prone to develop
ARF following administration of radiographic con-
trast media. The factors that predispose the diabetic
patient to ARF following the use of radiocontrast
media are (1) age greater than 55 years, (2) presence
of renal insufficiency, (3) the presence of diabetes
for more than 10 years with vascular complica-
tions, neuropathy, and retinopathy, (4) proteinuria,
(5) dehydration, and (6) recent administration of
nephrotoxic drugs. Many of these factors are simi-
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Table 1. Urinary diagnostic indices for prerenal azotemia (PA), acute oliguric renal failure (AORF), acute nonoliguric renal failure
(ANRF), acute obstructive uropathy (AOU), and acute glomerulonephritis (AG)'
PA AORF ANRF AOU AG
Urineosmolality,mOsm/kgofwater 518 35 369 20 343 17 393 39 385 61
Urine sodium, mEqiliter 18 3 68 5 50 5 68 10 22 6
Urine/plasmaurea nitrogen ratio 18 7 3.0 0.5 7 1 8 4 11 4
Urine/plasma creatinine ratio 45 6 17 2 17 2 16 4 43 7
Renalfailureindex(seetext) 0.6 0.1 10 2 4 0.6 8 3 0.4 0.1
Fractionalexcretionoffilteredsodium(%) 0.4 0.1 7.0 1.4 3.0 0.5 6 2 0.6 0.2
Values are expressed as Mean 1 SEM. Data taken from Ref. 63 reproduced with permission of Annals of Internal Medicine.
lar to those that predispose patients to amino-
glycoside nephrotoxicity. It should also be empha-
sized that nondiabetic patients without myeloma or
hyperuricemia may be predisposed to ARF from
contrast media studies 1161]. Preexisting renal dis-
ease and advanced age are probably the most im-
portant factors in these patients. Contrast media-in-
duced ARF is characterized by a rapid onset of oh-
guria, with a peak serum creatinine concentration
reached within 3 to 6 days, followed by gradual re-
covery. Those patients with markedly elevated
serum creatinine concentrations (>3 to 6 mg/100
ml), however, may develop irreversible ARF [62].
Careful examination of the urine sediment and
analysis of the biochemical composition of the urine
are very important in the diagnosis of ARF. As al-
ready emphasized, urinary eosinophils suggest in-
terstitial nephritis, whereas RBC casts suggest vas-
culitis or glomerulonephritis. A normal urine sedi-
ment suggests the presence of prerenal or post renal
azotemia.
In a recent prospective study from our laborato-
ry, several urinary findings were evaluated to assess
their diagnostic value in patients with azotemia [63].
The results of this study are shown in Table 1. In
those patients whose azotemia was reversible by
correction of a prerenal factor (e.g., volume deple-
tion) within 24 hours, the urinary indices were gen-
erally as follows: urinary osmolality >500 mOsmlkg
of water, urinary sodium <20 mEq/hiter, urine to
plasma urea nitrogen ratio >8, and urine to plasma
creatinine ratio >40. By contrast in those patients
who followed a course of oliguric renal failure, the
urinary indices were generally: Urinary osmolahity
<350 mOsmlkg of water, urinary sodium >40 mEqI
liter, urine to plasma urea nitrogen ratio <3, and
urine to plasma creatinine ratio <20. In general, pa-
tients with acute glomerulonephritis had urinary in-
dices similar to those observed with prerenal azo-
temia, and patients with azotemia secondary to uri-
nary tract obstruction had urinary indices similar to
oliguric ARF. The urinary indices of patients with
nonohiguric (>800 mllday) renal failure were similar
to oliguric renal failure except the mean urinary so-
dium concentration was somewhat lower. Urinary
sodium concentrations (<20 mEq/hiter) in our non-
ohiguric patients were however not as low as those
observed by Vertel and Knochel [64] in burn pa-
tients; perhaps the large volumes of crystalloid-free
solutions administered to burn patients with nonoli-
guric renal failure account for their much lower uri-
nary sodium concentrations. Although these uri-
nary indices were discriminating in 80% of patients,
approximately 20% of patients had indices in an in-
termediate, nondiagnostic zone (e.g., urinary Os-
molality, 350 to 500 mOsmlkg; urinary sodium, 20
to 40 mEq/liter; urine to plasma urea nitrogen ratio,
3 to 8; and urine to plasma creatinine ratio, 20 to
40). This nondiagnostic zone could be narrowed,
however, by the use of such derived indices as the
"renal failure index" [(urinary sodium, mEq/liter)/
(urine to plasma creatinine ratio)] and the fractional
sodium excretion index [(urine to plasma sodium ra-
tio)/(urine to plasma creatinine ratio) x 100]. These
two measures tended to be <1 in prerenal azotemia
and >1 in patients with ohiguric or nonoliguric renal
failure.
Those patients whose urinary indices fell within
the nondiagnostic zone may well have been pro-
gressing from prerenal azotemia to ARF. It is
tempting to suggest that it is this group of patients,
in fact, who might benefit from prophylactic mea-
sures designed to prevent the development of ARF.
In this regard, there is recent evidence suggesting
that the efficacy of prophylactic measures relates to
their ability to increase the rate of solute excretion;
increased solute excretion, in turn, may exert its ef-
fect by attenuating secondary tubular obstruction
[46, 65]. Although the renin-angiotensin system [66]
and cell swelling [671 have been proposed as vascu-
lar mediators in the pathogenesis of ARF, prophy-
laxis in experimental ARF can be dissociated from
renal tissue renin [68] and extracellular fluid os-
molality [46]. Administration of isotonic or hyper-
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tonic mannitol or furosemide with prompt replace-
ment of urinary losses is most effective in increasing
solute excretion rate and attenuating the ARF in-
duced by low doses of norepinephrine [46, 551.
Those measures that increase solute excretion
may also have the capacity to convert oliguric to
nonoliguric renal failure. This effect on urine flow
may be quite important in view of a recent study in
patients with azotemia that demonstrated a lower
mortality in nonoliguric versus oliguric renal failure
(26% versus 50%, P <
.05) [24]. Morbidity (e.g.,
infection, gastrointestinal bleeding, fluid overload)
was also lower in patients with nonoliguric ARF,
and only 28% of these patients required dialysis as
compared to 84% of patients with oliguric ARF [24].
These beneficial effects associated with increased
urine flow occurred whether the nonoliguric ARF
was spontaneous or whether it had been converted
from an oliguric ARF by furosemide administration.
The results also provide some clues about which pa-
tients are more likely to convert from oliguric to
nonoliguric ARF in response to furosemide thera-
py. Those patients who responded to furosemide by
converting from oliguric to nonoliguric ARF had
significantly lower mean serum creatinine concen-
trations (3.8 mg vs. 5.0 mg/l00 ml), lower urinary
sodium concentrations (47 mEq vs. 67 mEq/liter),
and lower fractional sodium excretions (2.9 vs. 6.9)
as compared to those who remained oliguric [24].
These results suggest that early diagnosis through
appropriate assessment of urinary indices will be
essential if furosemide is to improve morbidity and
mortality in patients with ARF by inducing a nonoli-
guric state. As already suggested, it is conceivable
that evolution to ARF may be prevented by furose-
mide or mannitol in those patients whose urinary
indices are in the nondiagnostic transition zone be-
tween prerenal azotemia and ARF. Of course, the
use of these agents for this purpose is no substitute
for and should only follow correction of any pre-
renal factor that may be present, such as hypovo-
lemia or congestive heart failure. Moreover, a pro-
spective, randomized study remains to be per-
formed to document the efficacy of furosemide or
mannitol in preventing or attenuating ARF in man.
In this regard, past failures to demonstrate any effi-
cacy for furosemide in man [69] or in experimental
animals [701 may reflect administration of the agent
too late in the course of the ARF [69] or inadequate
replacement of urinary water and electrolyte losses
with consequent volume depletion [70]. In the pa-
tient discussed today, early assessment of urinary
indices, restoration of blood volume, and a trial
with furosemide might have converted an oliguric to
a nonoliguric ARF.
Treatment. The use of hemodialysis in the Kore-
an War diminished mortality of ARF from 95% to
approximately 50 to 75% [71]; since then, however,
the mortality among patients with traumatic ARF
has not diminished further [72]. Certainly, much of
the mortality in ARF is due to a complicating illness
or illnesses. Nevertheless, since infection still re-
mains the primary cause of death, it is possible that
the uremic state predisposes to these infections
[73]. Thus, more efficient and earlier dialysis might
further diminish the mortality rate in ARF. In this
regard, some studies suggest that early dialysis, pri-
or to the onset of uremic symptoms may decrease
mortality in ARF. This prophylactic approach in-
volves using dialysis to maintain the serum creati-
nine concentration below 8 to 10 mgIlOO ml and the
BUN concentration below 100 mg/l00 ml. This
method, however, may still not be adequate to
avoid some complications of uremia, such as the in-
creased frequency and severity of infections.
Some evidence in support of this possibility is de-
rived from a small series of military casualties in
Viet Nam [74]. Two groups of comparably trauma-
tized casualties were studied. In one group in which
the BUN concentration was maintained below 50
mg/l00 ml and the serum creatinine concentration
below 5 mgIlOO ml, the mortality was 37% (three of
eight patients died); whereas in another group in
which the BUN concentration was maintained only
below 120 mg/l00 ml and the serum creatinine con-
centration below 10 mg!100 ml, the mortality was
80% (eight often patients died). Based on these lim-
ited findings, it would seem reasonable to explore
further the possibility that a dialysis schedule more
aggressive than presently used for "prophylaxis"
might further decrease the mortality of ARF. With
respect to the patient discussed here, arrangements
to transfer her for dialysis at a time when the serum
creatinine and BUN concentrations had already
reached 12 mg and 130 mg/lO0 ml, respectively,
were made somewhat late in her course. An earlier
transfer would have allowed for earlier evaluation
and dialysis.
Fluid restriction, as undertaken in this patient, is
appropriate in patients with oliguric ARF. It should
be remembered, however, that patients with nonoli-
guric renal failure must receive adequate fluid and
electrolytes to replace urinary and insensible
losses. Failure to provide such fluid and electrolyte
replacement in this setting may convert nonoliguric
ARF to oliguric ARF with its attendant higher mor-
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Table 2. Biochemical parameters suggesting hypercatabolism in
patients with acute renal failure
BUN >30 mg/100 ml per day increase
Serum creatinine >1 mg/l00 ml per day increase
Serum potassium >1 mEq/liter per day increase
Serum uric acid >15 mg/100 mla
Serum phosphate >8 to 10 mgIlOO ml, frequently with
severe hypocalcemia <6 mgIlOO ml
Serum bicarbonate >2 mEq/liter per day decrease
a Urine uric acid to creatinine ratio >1 suggests hyperuricemia
was cause rather than consequence of acute renal failure. Data
taken from Ref. 77.
bidity and mortality. This elderly woman was treated
with a low-protein Giovanetti diet prior to institu-
tion of hemodialysis. Although this diet may be of
value in chronic renal failure, its use in ARF is
probably not appropriate. Restriction of protein, al-
beit of high quality, may indeed retard the rate of
development of azotemia and delay the need for he-
modialysis. On the other hand, Abel, Beck, Abbott,
et al [75] have demonstrated that hyperalimentation
with glucose and amino acids—the so-called renal
failure fluid—is associated with more rapid recov-
ery of patients with ARF as well as with a lower
mortality in those patients who required dialysis.
Although this prospective study awaits confirma-
tion, it seems appropriate, particularly in patients
who are hypercatabolic because of fever, trauma,
or rhabdomyolosis, to institute hyperalimentation
using a similar type of parenteral fluid. Further sup-
port for this approach is provided by the observa-
tion that amino acid supplementation enhances re-
covery from experimental ARF [76].
The choice of either peritoneal dialysis or hemo-
dialysis, depends on a number of factors including
the availability of equipment and trained personnel
for hemodialysis. Although hemodialysis has cer-
tain disadvantages, such as greater hemodynamic
stress, the requirement for anticoagulation, a need
for vascular access, and a higher incidence of the
dysequilibrium syndrome, it is much more efficient
and clearly the method of choice in the hyper-
catabolic patient. The state of catabolism in the pa-
tient with ARF is often apparent from the clinical
history and can be gauged by the rate of biochemi-
cal changes. General biochemical guidelines for de-
termining whether a patient is catabolic or non-
catabolic are listed in Table 2. Peritoneal dialysis is
a simpler and more economical means of dialysis
and is quite acceptable in the noncatabolic patient,
barring recent intraabdominal surgery or the pres-
ence of abdominal adhesions. A major disadvantage
is the elevation of the diaphragm produced by the
fluid in the peritoneal cavity; diaphramatic immobil-
ity may lead to pulmonary complications such as
atelectasis and pneumonia and worsen chronic ob-
structive pulmonary disease, if present.
In closing, it is well to remember the quote by
Smith [78], which highlights the importance of nor-
mal renal function in man: "Bones can break, mus-
cles can atrophy, glands can loaf, even the brain can
go to sleep, without immediately endangering our
survival; but should the kidneys fail . . . not bone,
muscle, gland, nor brain could carry on."
Questions and Answers
DR. J. T. HARRINGTON: What was the time
course over which intratubular pressures were mea-
sured in the experimental model of ARF evoked by
clamping of the renal artery [41, 43]?
DR. R. W. SCHRIER: At approximately 2 to 4
hours, intratubular pressures were increased, but at
24 hours they were normal. At 24 hours, however, if
sufficient saline solution was administered to re-
store RBF to normal, intratubular pressures were
found to be increased. Other studies using the ex-
perimental model of ARF produced by norepineph-
rifle in low doses [44, 46] also have demonstrated
that intratubular pressures are higher than normal
when the RBF is returned to control levels.
DR. J. T. HARRINGTON: Do intratubular pres-
sures in the low-dose norepinephrine model of ARF
fall back to normal after a few days even though
normal renal hemodynamics are maintained? If in-
tratubular pressures are elevated sufficiently by
tubular obstruction, filtration might well cease, al-
lowing tubular pressure to return to normal.
DR. R. W. SCHRIER: To my knowledge there are
insufficient data to answer your question, but your
proposal seems likely. For example, complete ure-
teral ligation will increase intratubular pressures,
which will eventually return to normal through one
or more mechanisms that are not well understood
such as tubular compliance, and reflex pathways.
Thus, an element of tubular obstruction is difficult
to exclude at almost every stage of ARF even
though the absolute intratubular pressures are not
found to be elevated at all times.
DR. F. J. GENNARI (NEMCH): I would like to
sound a note of caution in the use of a single overall
mortality figure of 50 to 60% for ARF. It is well rec-
ognized that ARF can be divided into subgroups
with widely divergent mortality rates. For example,
mortality may be near zero in young patients with
ARF induced by a nephtrotoxin or an incompatible
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blood transfusion; by contrast, patients with ARF
and severe trauma or extensive burns may have a
mortality rate of 80 to 100%. In order for a prospec-
tive study to provide truly useful information con-
cerning the value of a particular treatment in pa-
tients with ARF, the patients in each study group
should be paired according to the illness on which
the ARF is superimposed.
DR. R. W. SCHRIER: These are good points. A
related question is whether the failure to reduce the
mortality in ARF over the last 30-odd years is ex-
plained by the fact that we are dealing with sicker
patients. That is to say, if we could go back two to
three decades and apply our modern techniques,
could we bring the mortality rate down to 20%?
This contention can be neither proved nor dis-
proved. It could be argued that some of the changes
in the mix of patients with ARF over the past 30
years should actually have improved the mortality
figures. For example, the mortality rate of patients
with aminoglycoside-induced ARF may be as low
as 18% [24]. There is no question that any study of a
randomized large group of patients with ATN con-
taining comparable numbers of good-risk and poor-
risk subgroups, would be most helpful. Granted, to
pair patients may be even better, but it is very hard
to obtain adequate numbers of patients using this
approach.
DR. J. P. KA5sIRER: How do you interpret the re-
cent micropuncture study of ARF by Bayliss et al
[79] on glomerular permeability with aminoglyco-
sides? As I recall, these investigators suggested that
the reduction in filtration coefficient (Kt) might be
responsible for the decrease in glomerular function,
at least in their particular rat model.
DR. R. W. SCHRIER: That study demonstrated
that rats given 4 mg/kg of gentamicin had a measur-
able reduction in GFR, which could be explained
largely on the basis of a diminished Kf. The magni-
tude of the fall in GFR was not sufficient to cause
azotemia, but it certainly could be a potential con-
tributing pathogenetic mechanism.
DR. J. P. KA5SIRER: Might a larger dose of an
aminoglycoside produce a greater diminution in Kf
and GFR?
DR. R. W. SCHRIER: In the study by Bayliss et al
[79] the decrease in Kf in the group of rats receiving
40 mg/kg was not greater than a group of rats receiv-
ing 4 mg/kg. The decrease in GFR was greater in the
group receiving 40 mg of gentamicin, thus demon-
strating the importance of other glomerular factors.
Of course, it is always possible that results obtained
using these very large doses of aminoglycosides in
rats may not be directly applicable to man.
DR. J. J. COHEN: Your comments suggested that
gentamicin-induced ATN may be slowly progres-
sive and may continue to worsen after administra-
tion of the agent is discontinued. In your experi-
ence, how long can the serum creatinine concentra-
tion continue to increase once the drug is stopped?
DR. R. W. SCHRIER: Because aminoglycosides
accumulate and persist in the renal cortex, discon-
tinuation of the drug will not rapidly reverse the
azotemia and improvement may take several days
to weeks.
RENAL FELLOW: In evaluating a patient suspect-
ed of having ATN, do you think it is necessary to
obtain a urine to plasma creatinine ratio as well as a
urinary sodium concentration?
DR. R. W. SCHRIER: As mentioned earlier, I think
there is some evidence for a nondiagnostic zone in
which patients who are evolving from prerenal fail-
ure to ATN may fall [63]. This area of overlap be-
tween prerenal failure and ATN seems to be smaller
when the renal failure index (urinary sodium/urine
to plasma creatinine) is used. Before we performed
our study, my bias was that the urine to plasma
creatinine ratio would be more valuable than the
urinary sodium concentration; this possibility was
not substantiated. We had a 20% overlap of patients
whether the urinary sodium concentration or urine
to plasma creatine concentration was used. Com-
bining this information in the renal failure index was
helpful, however. Even so, a significant percentage
of patients still fall into a nondiagnostic zone.
DR. J. J. COHEN: In your study [24], what criteria
were used to assign patients into the ATN group?
DR. R. W. SCHRIER: This categorization was
done by correcting all prerenal factors that could be
identified; those patients in whom azotemia was re-
versed within 24 hour by correction of prerenal fac-
tors were considered to have had prerenal failure.
We also excluded urinary tract obstruction, which
occurred in 8% of the patients with azotemia. This
latter exclusion was important, since the urinary in-
dices with obstruction were similar to those in
ATN. Thus, a diagnosis of ATN was made by ex-
cluding prerenal and postrenal (obstructive) causes
of azotemia.
DR. N. E. MADIA5 (NEMCH): What constitutes
an adequate trial with furosemide?
DR. R. W. SCHRIER: It is known that furosemide
may induce a significant diuresis when the GFR is
less than 10 mI/mm. A dose of 300 to 600 mg of fu-
rosemide may be necessary, however, to induce a
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diuresis in the presence of either advanced acute or
chronic renal impairment.
DR. J. J. COHEN: Some have argued that adminis-
tration of mannitol is a useful prophylactic maneu-
ver, for example in patients undergoing abdominal
aortic aneurysm surgery. Considering the informa-
tion you now have, do you think pretreatment of
high-risk patients with furosemide would be worth-
while?
DR. R. W. SCHRIER: On the basis of our experi-
mental studies in low-dose norepinephrine-induced
ARF [46, 47, 55, 65], the common parameter of pro-
phylaxis seemed to oe increased solute excretion,
not the particular agent used. Thus, furosemide ad-
ministration should theoretically be as effective as
mannitol if volume depletion is avoided. In the ab-
sence of volume depletion, the large volumes of ad-
ministered saline necessary to achieve solute excre-
tion rates comparable to those obtained following
mannitol or furosemide administration makes saline
a less desirable prophylactic agent.
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